The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype

ZEB2 function exerts opposing behaviors in melanoma by promoting proliferation and expansion and conversely inhibiting invasiveness, which could be of future clinical relevance. Epithelial-to-mesenchymal transition (EMT)-inducing transcription factors (TF) are well known for their ability to induce mesenchymal states associated with increased migratory and invasive properties. Unexpectedly, nuclear expression of the EMT-TF ZEB2 in human primary melanoma has been shown to correlate with reduced invasion. We report here that ZEB2 is required for outgrowth for primary melanomas and metastases at secondary sites. Ablation of Zeb2 hampered outgrowth of primary melanomas in vivo, whereas ectopic expression enhanced proliferation and growth at both primary and secondary sites. Gain of Zeb2 expression in pulmonary-residing melanoma cells promoted the development of macroscopic lesions. In vivo fate mapping made clear that melanoma cells undergo a conversion in state where ZEB2 expression is replaced by ZEB1 expression associated with gain of an invasive phenotype. These findings suggest that reversible switching of the ZEB2/ZEB1 ratio enhances melanoma metastatic dissemination. Significance: ZEB2 function exerts opposing behaviors in melanoma by promoting proliferation and expansion and conversely inhibiting invasiveness, which could be of future clinical relevance. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/80/14/2983/F1.large.jpg. Graphical Abstract

[1]  C. Deng,et al.  SMAD signaling promotes melanoma metastasis independently of phenotype switching. , 2019, The Journal of clinical investigation.

[2]  Monika S. Kowalczyk,et al.  A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade , 2018, Cell.

[3]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[4]  J. Gershan,et al.  E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells , 2016, Oncotarget.

[5]  S. Aerts,et al.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.

[6]  Douglas B. Johnson,et al.  Treatment of NRAS-Mutant Melanoma , 2015, Current Treatment Options in Oncology.

[7]  G. Berx,et al.  Melanoma Cells Revive an Embryonic Transcriptional Network to Dictate Phenotypic Heterogeneity , 2014, Front. Oncol..

[8]  N. Haass,et al.  Real‐time cell cycle imaging during melanoma growth, invasion, and drug response , 2014, Pigment cell & melanoma research.

[9]  A. Puisieux,et al.  Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.

[10]  G. Berx,et al.  Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression , 2014, Cell Death and Differentiation.

[11]  M. Tatari,et al.  ZEB2-transgene expression in the epidermis compromises the integrity of the epidermal barrier through the repression of different tight junction proteins , 2014, Cellular and Molecular Life Sciences.

[12]  A. Postigo,et al.  GLI2 cooperates with ZEB1 for transcriptional repression of CDH1 expression in human melanoma cells , 2013, Pigment cell & melanoma research.

[13]  J. Lachuer,et al.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. , 2013, Cancer cell.

[14]  J. Massagué,et al.  Review Origins of Metastatic Traits , 2022 .

[15]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[16]  T. Brabletz EMT and MET in metastasis: where are the cancer stem cells? , 2012, Cancer cell.

[17]  Hubing Shi,et al.  MDM4 is a key therapeutic target in cutaneous melanoma , 2012, Nature Medicine.

[18]  S. Middendorp,et al.  PHF19 and Akt control the switch between proliferative and invasive states in melanoma , 2012, Cell cycle.

[19]  K. Hoek,et al.  GLI2 and M‐MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells , 2011, Pigment cell & melanoma research.

[20]  D. Peeper,et al.  Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis , 2011, Oncogene.

[21]  A. Weeraratna,et al.  Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching , 2011, Pigment cell & melanoma research.

[22]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[23]  A. Weeraratna,et al.  The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report , 2010, Melanoma research.

[24]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[25]  Andreas Janshoff,et al.  Dynamics of human cancer cell lines monitored by electrical and acoustic fluctuation analysis. , 2010, Integrative biology : quantitative biosciences from nano to macro.

[26]  C. Print,et al.  A Gene Expression Signature of Invasive Potential in Metastatic Melanoma Cells , 2009, PloS one.

[27]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[28]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[29]  L. Larue,et al.  Spatiotemporal gene control by the Cre‐ERT2 system in melanocytes , 2006, Genesis.

[30]  L. Nelles,et al.  Generation of the floxed allele of the SIP1 (Smad‐interacting protein 1) gene for Cre‐mediated conditional knockout in the mouse , 2002, Genesis.

[31]  Shankar Srinivas,et al.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus , 2001, BMC Developmental Biology.

[32]  R. Dummer,et al.  Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. , 1998, The Journal of investigative dermatology.

[33]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[34]  Joachim Wegener,et al.  Real-time impedance assay to follow the invasive activities of metastatic cells in culture. , 2002, BioTechniques.